Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.

Trial Details

NCT ID
NCT05789303
Phase
PHASE2
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Belantamab mafodotin
  • Carfilzomib
  • Pomalidomide
  • Dexamethasone
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Subject must not use contact lenses while participating in this study unless instructed by an ophthalmologist.
  • Subject must not be simultaneously enrolled in any interventional clinical trial.
  • Subject must not have had major surgery ≤ 2 weeks prior to initiating study treatment.
  • Subject must not have any evidence of active mucosal or internal bleeding.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →